EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The collaboration will center on expanding access to Eastman’s Esmeri technology
The new functionality complements Parse’s existing Evercode immune products
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
